Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer

K. Haslett,P. Koh,A. Hudson,W.D. Ryder,S. Falk, D. Mullan,B. Taylor,R. Califano,F. Blackhall,C. Faivre-Finn

Clinical and Translational Radiation Oncology（2021）

引用 4|浏览5

暂无评分

摘要

•Single-arm, single-centre, open-label phase I trial.•Stage III or low burden stage IV non-small cell lung cancer (NSCLC) (n = 21).•Treatment with MEK inhibitor selumetinib concomitantly with radiotherapy.•Combination feasible but outcomes poor and large incidence of pneumocystis jiroveci pneumonia.

查看译文

关键词

NSCLC,Selumetinib,Thoracic radiotherapy,MEK inhibitor,Lung cancer,Phase I

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要